Servier eyes up Ideaya’s darovasertib
As pivotal data approach, the French group pays $210m for ex-US rights.
Ideaya eyes neoadjuvant uveal melanoma
But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.
